AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

May 28, 2026
, 6:44 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acquisition.

The post AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer appeared first on MedCity News.

Leave a Replay

Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward

Winona Launches Menopause Research Initiative

Shifting Our Focus to Sample Sensitivity: The Metric That Deserves More Attention in Respiratory Care

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

Leave a Replay

Related Posts

Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward

Winona Launches Menopause Research Initiative

Shifting Our Focus to Sample Sensitivity: The Metric That Deserves More Attention in Respiratory Care

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us